Right off the top, I apologize for the obviousness of the Mr. Spock reference. I couldn’t resist! A few months ago I was invited by Robert Kirsner, MD, PhD and Stephanie Wu, DPM to write a chapter on “Antimicrobial Therapy” …
Read more →
Antibiotics
Page 4
Those of you who have read my chapter on MRSA in the 3rd Edition of the Handbook of Lower Extremity Infections (haven’t you all by now?!) or listened to me lecture about MRSA know that I am less than happy …
Read more →There is a small group of us that, when we find an interesting article dealing with infections, we pass them on so we can all be stay up to date. Some of the journals are fairly obscure and are not …
Read more →I will be in Columbus, OH for the Region IV (Ohio) meeting to lecture on June 3, 2010. I have been given the “Learning Lunch” spot from 12:00 to 1:30 and plan on covering a broad range of lower extremity …
Read more →I just returned from a lecture trip to Turkey where I had the privilege of giving 5 talks, one in the Mediterranean resort city of Antalya at a nationwide Hospital Infection Congress and 4 to the faculties at various medical …
Read more →(My thanks to David Armstrong, DPM, PhD for bringing this press release to my attention) TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints According to its manufacturer TaiGen, nemonoxacin, a novel, non-fluorinated quinolone has …
Read more →For a number of years I have been presenting a lecture entitled “Differentiating infected from non-infected wounds”. As part of that talk I discuss the role of topical antimicrobials in wound healing. Despite there being a countless number of silver …
Read more →Two studies published in the January 7, 2010 issue of the New England Journal of Medicine have received a tremendous amount of play in the popular press. One paper out of Baylor in Houston looked at comparing chlorhexidine + alcohol …
Read more →Telavancin (Vibativ – Theravance/Astellas) is a novel lipoglycopeptide, related to vancomycin, that has been recently approved by the FDA for the treatment of complicated skin and skin structure infections (cSSSI) caused by MRSA. Telavancin now joins the ranks of vancomycin, …
Read more →Some interesting news just came out yesterday. It looks like J&J’s new anti-MRSA cephalosporin, ceftobiprole has been, once again, turned back by the FDA. See the story here: http://money.cnn.com/news/newsfeeds/articles/marketwire/0572888.htm Many of us had pretty high hopes for this antibiotic as …
Read more →